



Press Release

Astellas and Viatriis Announce Termination of Co-promotion, Succession of Manufacturing and Marketing Approval, and Transfer of Distribution for Celecox[®] Tablets

TOKYO, December 7, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Viatriis Pharmaceuticals Japan Inc. (Country Manager: Sun-A Kim, "Viatriis") announced that the two companies have agreed to end the joint sales promotion (co-promotion) of the non-steroidal anti-inflammatory and analgesic "Celecox[®] Tablets 100mg, 200mg" (generic name: celecoxib, "Celecox") manufactured and sold by Astellas and co-promoted by both companies in Japan on December 31, 2020.

In accordance with this agreement, Celecox promotion, which to date has been carried out jointly by both companies, will be conducted solely by Viatriis as of January 1, 2021. Astellas will continue its distribution until the termination of the agreement on July 31, 2021, after which time Viatriis will be the Marketing Authorization Holder of Celecox.

In Japan, Celecox was launched for the indication of "relief of inflammation and pain associated with rheumatoid arthritis and osteoarthritis" in June 2007. Subsequently, "relief of inflammation and pain associated with lumbago, scapulohumeral periarthritis, cervico-omo-brachial syndrome, and tendinists / tendosynovitis" were approved as additional indications in June 2009. In December 2011, "anti-inflammatory / pain relief after surgery, trauma, and tooth extraction" were also approved as additional indications.

The impact of this transaction on Astellas' financial results for the fiscal year ending March 31, 2021 is expected to be minor.

About Viatris

Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway™. Formed in November 2020 through the combination of Mylan and Pfizer's Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at [viatris.com](https://www.viatris.com) and investor.viatris.com.

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at <https://www.astellas.com/en>.

Cautionary Notes (Astellas)

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.

Corporate Advocacy & Relations

TEL: +81-3-3244-3201 FAX: +81-3-5201-7473

Viartis Pharmaceuticals Japan Inc.

Communications

TEL: +81-3-3261-7715 FAX: +81-3-3261-7174